Background: Self-monitoring of blood glucose (SMBG) is a key pillar of personal diabetes management. The objective of this observational study was to analyze diabetes self-management (DSM) and glycemic outcomes before and during system implementation in real-life settings of a blood glucose meter system with a color-coded display of glucose levels, which helps identify out-of-range levels.
Original Article
Self-monitoring of blood glucose (SMBG) plays an important role in diabetes management.
1,2 SMBG has been shown beneficial for the achievement of glycemic targets and reducing glycemic variability, allowing even for hypoglycemia anticipation. [3] [4] [5] [6] In patients with type 2 diabetes treated with insulin, SMBG is not only associated with an improved metabolism, it also strengthens patient responsibility, [7] [8] [9] [10] [11] increasing disease awareness thereby influencing lifestyle. 12 Furthermore, an epidemiological cohort study demonstrated a positive influence of frequent SMBG on diabetes-related morbidity and overall mortality. 13 Various national and international guidelines recommend regular SMBG for diabetes management and treatment support. The American Diabetes Association guideline recommends SMBG to both health providers and patients for glycemic control assessment. 1 Additional recommendations, such as the guidelines by the International Diabetes Federation (IDF), 14 the European Society of Cardiology (ESC), 15 and the European Association for the Study of Diabetes (EASD) 16 consider SMBG an integral part of diabetes self-management (DSM). Moreover, European consensus Neuss, Germany) is a new blood glucose meter that informs users via a color-coded display system whether the measured values are within (green), below (blue) or above (red) their target range, which would be individually tailored to the patient by their health provider. It provides easy-to-understand measurement results, increasing patient awareness, thus allowing for better self-management of their blood glucose levels, irrespective of whether exercise, food choice or insulin dose adjustment is required. The system stores measurements and therefore allows for tracking progress. Patients are informed and encouraged by the system via automatic on-screen messages. For instance, continuously within-target values, or getting back into range after being too high are reaffirmed by success messages.
21-23 A summary of device features can be observed in Figure 1 .
In this observational study, we intended to analyze DSM before and during system implementation in real-life settings and demonstrate its effects on glycemic control.
Methods
We performed a national multicenter (9 trial sites) prospective observational study. The trial was performed in agreement with the requirements from the Bavarian Medical Council. All patients provided written informed consent after being properly informed in writing about the objectives and particulars of the study. The duration of the observational study was 6 months; values were analyzed upon launch (baseline), at 3 months and at 6 months.
Biological parameters examined included blood glucose and HbA1c levels, which were evaluated by means of quality-controlled laboratory methods as were lipids (LDL, HDL, and triglycerides). For analysis of biological factors, the usually accepted reference values/intervals were employed. Anthropometric data included the patient's body mass index (BMI) and waist size. Therefore, weight and height were noted at baseline and weight followed up over the course of the study. To get a general overview over the patient's general health status, relevant medical data (ie, diabetes-related diseases) was extracted from the patient's medical history. Moreover, systolic and diastolic blood pressures were monitored throughout the study.
Patients with type 1 diabetes and patients with type 2 diabetes were eligible if they had been treated with insulin for at least 6 months prior to enrollment. Key inclusion criteria were a glycated hemoglobin level of 7.5% or more, and a good knowledge of SMBG plus regular blood glucose metering for at least 6 months or longer before inclusion. Key exclusion criteria included known diabetes mellitus without insulin treatment, febrile diseases upon enrolment and/or gastric resection, or any sort of pancreas condition (chronic pancreatitis, pancreatic cancer, total pancreatectomy, hemochromatosis or cystic fibrosis). Endocrine disorders such as hypercortisolism, hyperthyroidism, Addison's disease, Cushing's disease, pheochromocytoma, acromegaly, Conn syndrome or glucagonoma, or cortisone therapy precluded patient recruitment. Under age (<18 years old), pregnant or breast-feeding patients were also excluded from participation in the study.
Patients provided their information/data during their regular care visits to the recruitment centers: At baseline, where they provided informed consent on trial participation and two further visits 3 and 6 months after study initiation. In addition, patients were instructed on meter use and their personal glucose targets established with their health care provider.
In each visit, patients were questioned about SMBG frequency and biological parameters like HbA1c and blood glucose, among others, were evaluated for further comparison. As data were extracted from routine patient visits, there was no extra requirement to analyze any biological parameter such as lipids or else. Patients were also asked to fill out a validated Diabetes Self-Management Questionnaire (DSMQ) consisting on 16 distinct questions on various points, 24 to assess the possible changes to their disease self-management brought about by the intervention, that is, by use of the OneTouch meter in their daily SMBG routines. DSMQ subscales ("Glucose Management," questions 1, 4, 6, 10, 12; "Dietary Control," questions 2, 5, 9, 13; "Physical Activity," questions 8, 11, 15; "Health-Care Use," questions 3, 7, 14) scores were calculated according to Schmitt et al. 24 A total score "Sum Score" including all DSMQ questions and representative of overall DSM was also calculated as in Schmitt et al. 24 Moreover, in the follow-up visits at 3 and 6 months after trial launch, patients and diabetes educators at the recruitment sites were asked to submit further satisfaction evaluations by filling out a short binary (yes/no) questionnaire. A description on the content of the three questionnaires can be found in Table 1 . 7. I tend to avoid diabetes-related doctors' appointments. 3 2 1 0 8. I do regular physical activity to achieve optimal blood sugar levels.
9. I strictly follow the dietary recommendations given by my doctor or diabetes specialist.
10. I do not check my blood sugar levels frequently enough as would be required for achieving good blood glucose control.
11. I avoid physical activity, although it would improve my diabetes.
12. I tend to forget to take or skip my diabetes medication (eg, insulin, tablets).
13. Sometimes I have real "food binges" (not triggered by hypoglycemia). I believe the color-cue on the Range Indicators offers patients ability to instantly see where they are in their personal glucose range.
3

1 0
2. I believe the instant messages displayed on the meter will provide my patients with timely feedback so they can take immediate action, if needed.
3. I believe the using the OneTouch Verio will help my patients feel more engaged in their diabetes care.
Patient Satisfaction Questionnaire
Please specify the extent of agreement with each statement. Yes No 1.
Without any extra effort, it lets me know if my results are in or out of range.
2.
Gives me useful information about my results without extra effort. 1 0 3.
Helps me to better understand my results so I can make better decisions. 1 0 4.
The automatic 7-day average makes it easy to see how I am doing over time.
5. Does the color-coded range indicator help to understand the results? 1 0 6.
Are the progress notes and the in-range results a better motivation for the implementation?
Target criteria for the observational study include changes in subjective perceptions regarding diabetes management as well as changes in laboratory parameters. The primary endpoint was the DSMQ "Sum Score." It was analyzed in 136 patients, in whom the DSMQ was obtained at all three visits. The analysis of the DSMQ subscales was part of secondary endpoints. The additional important secondary endpoint was changes to HbA1c levels.
Data
Results
From July 2015 until January 2016, a total of 193 patients were screened and enrolled in the study; of these patients, 150 (77.7%) attended the last follow-up visit at an investigator site.
Demographic and clinical characteristics of the patients at baseline are summarized in Table 2 . Average age was 60 years old and 106 (54.9%) were male. 172 (89.1%) were patients with T2DM under insulin treatment, while the rest were patients with T1DM. The overall mean diabetes duration was 13.7 years, and the mean glycated hemoglobin level was 8.68%. At baseline, the average SMBG reported frequency was over three times a day (3.34 ± 1.49). Insulin therapy at baseline consisted on average of 67.8 ± 48.7 (IE) per day, where 49.6 ± 36.6 IE corresponded to postmeal insulin and a further 30.5 ± 15.9 IE to basal insulin. Furthermore, nearly 60% of patients received metformin; other antidiabetic medications, like GLP-1 RA or DPP-4 inhibitors were also part of the standard diabetes therapy, but were used by far less patients as metformin (13.4 and 12%, respectively). In association with a study population with a majority of T2DM, patients were on average overweight as demonstrated by average BMI (29.3 ± 5.78).
As expected from patients with a relatively long disease duration, many patients suffered from diabetes-related microvascular ailments such as polyneuropathy (46.8%), foot syndrome (12.2%), retinopathy (11.5%) or nephropathy (23.1%). In association with renal damage, 36.3% of enrolled patients suffered from proteinuria (31.8% microalbuminuria; 5.95% macroalbuminuria). The lipid status of patients at enrollment showed hyperlipidemia in 60.1% of cases, with average total cholesterol levels of 198 ± 56.9 mg/dl, and triglyceride, HDL and LDL cholesterol levels within healthy limits but nearly out of range (Table 2 ). Since high blood pressure is associated with diabetes, hypertension was also found in almost 74% of enrolled patients, with an average systolic and diastolic blood pressure of 139 ± 18.3 mmHg and 83.2 ± 10.3 mmHg, respectively.
In terms of primary end-point assessment, the analysis of the changes in response patterns from patients to the DSMQ over the course of the study showed a significant improvement of the "Sum Score" (P = .039) observed at the end of the observation period. It also provides evidence supporting the overall improvement of patient self-management (Table 3 ). In certain patient attitudes toward diabetes management, as shown from the significant changes to 3 specific questions, namely: questions Q2 (P < .001), Q9 (P = .001) and question Q16 (P = .0046). The first two related to nutrition habits while the last one is a summary question reflecting overall satisfaction with own diabetes management. Moreover, shifting the focus to the subscale analysis, the same pattern of increased conscientiousness toward nutrition could be observed from the significant change to the subscale "Dietary Control" score (P = .004) ( Table 3) . Over the course of the study, there was a significant improvement of glycemic control as shown by the decrease both in HbA1c (P < .0001), that went from 8.7% at baseline to 8.13% after 3 months (P < .0001) and to 7.99% after 6 months; and fasting glucose levels (P = .0073), decreasing from 179 to 152 mg/dl (3-months) and to 147 mg/dl over the whole duration of the trial (Table 4) .
Other parameters such as BMI or body weight did not change over the course of the study, nor did the average blood pressure or the overall lipid status of study participants (Table 4) , even when a tendency toward improved total cholesterol levels could be detected (198 ± 56.9 to 193 ± 46.4 mg/dl; P = .0611).
SMBG frequency did also significantly increase during the intervention, demonstrating an increase of one more time a day to a total of nearly 4 times a day after 6 months (P < .05). Moreover, insulin therapy underwent significant changes over the study period, with progressively increasing doses in basal (30.5 ± 15.9 to 33.8 ± 17.4, P < .0001), postmeal (49.6 ± 36.6 to 52.7 ± 36.5, P < .0001), and total daily administration (67.8 ± 48.7 to 74.0 ± 49.1, P < .0001) ( Table 5) .
Three and six months after trial launch, both diabetes educators and the patients themselves believed, with between 72.3% to 96.2% agreement to the different satisfaction statements, that the use of the color coded SMBG meter OneTouch was helpful for DSM (Tables 6 and 7) .
Discussion
In this observational study, we could show that OneTouch, a color-coded display SMBG meter with extended functionality, 21 has significant effects on DSM during and after system implementation in real-life settings, and were able to demonstrate its effects on glycemic control.
The analysis of self-reported disease management via DSMQ, showed a significantly improved subjective perception on the quality of their personal diabetes management ("Sum Scale," P = .039; Q16, P = .0046); which was also shown both at the level of single questions and subscales, with a significant change in lifestyle attitudes (nutrition score: P = .004; Q2, P < .001, Q9, P = .001).
When asked about the influence of using the OneTouch meter in their DSM, both patients and diabetes educators agreed (72.3-96.2% assent) on its positive effects and usefulness for therapy adaptation. This self-reported improved diabetes management due to the use of the OneTouch meter over a continuous period of 6 months could have been the reason for the significant decrease of HbA1c levels (P < .0001) and fasting blood glucose (P = .0073) observed at the end of the study period. It is likely that the positive feed-back of the meter with its color signals and supporting comments motivated the patients to improve on their food habits as well as on adherence to the insulin therapy.
This improved self-management is also reflected by the significant change in blood glucose measurements/day observed after 6 months (P < .05) and, accordingly, by a better insulin therapy adaptation, as shown by the significant (P < .0001) increase in daily insulin dosing, be it total dose, basal, or postmeal injection. All in all, these data beg suggest the benefits of the device on the improved DSM and therefore on glycemic control.
No significant changes to body weight/BMI or other biological variables were observed over the span of the study, which could be explained due to the relative short duration of the trial for achievement of noticeable changes in certain parameters such as blood pressure or lipid status, even when a general tendency toward better total cholesterol levels was observed (P = .0611). Another possible explanation could be that the improvement in DSM is yet to reach the levels necessary to drive further metabolic changes. Further evaluation of long-term results of SMBG with the meter are necessary to either confirm or deny this possibility.
SMBG is recognized as a valuable tool for diabetes management, having been demonstrated to help patients achieve better biological outcomes, [3] [4] [5] [6] 13, [25] [26] [27] [28] [29] and to increase their disease self-awareness and improve on their management strategies, both at a clinical and lifestyle levels. 3, [7] [8] [9] [10] [11] 13, [30] [31] [32] [33] [34] The results of this 6-month observational study show that SMBG via OneTouch blood glucose meter, with its characteristics, including its color-coded display and easy-tounderstand results, contributes to helping not only to improve glycemic control but also to may lead to a better disease self-management.
Despite the positive results of the study, it is important to remember that as an observational study, patients were not blinded to study intervention, and we cannot disregard the possibility of certain study-related effects that might have 
Conclusion
In conclusion, this medium-term, real-life study demonstrates that OneTouch® Verio® assisted SMBG leads not only to a significant improvement in glycemic control, but also to a significant improvement in DSM.
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